Therini Bio, Inc.

Therini Bio Secures $39M in Series A Extension to Advance Novel Fibrin-Targeting Therapy for Neurodegenerative Diseases

8 days ago

• Therini Bio has raised $39 million in Series A extension financing, bringing total Series A funding to $75 million with support from new investors Angelini Ventures and Apollo Health Ventures. • The funding will advance Phase 1b trials of THN391, a first-in-class monoclonal antibody targeting fibrin-mediated neuroinflammation in Alzheimer's Disease and Diabetic Macular Edema. • THN391 demonstrated promising safety and pharmacokinetic profiles in Phase 1a trials, with no adverse hematological effects and a half-life supporting monthly dosing regimens.